Full View

Contemporary national patterns of eligibility and use of novel cardioprotective antihyperglycemic agents in type 2 diabetes mellitus

AA Nargesi, GP Jeyashanmugaraja… - Journal of the …, 2021 - Am Heart Assoc
Background SGLT‐2 (sodium glucose transporter‐2) inhibitors and GLP‐1RAs (glucagon‐
like peptide‐1 receptor agonists) effectively lowered cardiovascular risk in large clinical trials …
被引用次数：40 相关文章

Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus.

AA Nargesi, GP Jeyashanmugaraja… - Journal of the …, 2021 - europepmc.org
Background SGLT-2 (sodium glucose transporter-2) inhibitors and GLP-1RAs (glucagon-like
peptide-1 receptor agonists) effectively lowered cardiovascular risk in large clinical trials for …
[HTML] nih.gov

[HTML][HTML] Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus

AA Nargesi, GP Jeyashanmugaraja… - Journal of the …, 2021 - ncbi.nlm.nih.gov
Background SGLT‐2 (sodium glucose transporter‐2) inhibitors and GLP‐1RAs (glucagon‐
like peptide‐1 receptor agonists) effectively lowered cardiovascular risk in large clinical trials …

Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus

AA Nargesi, GP Jeyashanmugaraja, N Desai, K Lipska… - 2021 - Am Heart Assoc
BACKGROUND: SGLT-2 (sodium glucose transporter-2) inhibitors and GLP-1RAs
(glucagon-like peptide-1 receptor agonists) effectively lowered cardiovascular risk in large …

Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus

AA Nargesi, GP Jeyashanmugaraja… - Journal of the …, 2021 - pubmed.ncbi.nlm.nih.gov
Background SGLT-2 (sodium glucose transporter-2) inhibitors and GLP-1RAs (glucagon-like
peptide-1 receptor agonists) effectively lowered cardiovascular risk in large clinical trials for …